For three consecutive years, employer coverage of GLP-1 medications for weight loss expanded. That streak ended in 2026.

The Numbers

WTW's 2026 Best Practices in Healthcare Survey (471 US employers with at least 100 employees, together employing about 7 million people, released October 28, 2026):

53% cover GLP-1s for weight loss, down from 57%: the first decline in three years
30% of employers that still cover them are considering eliminating that coverage, per WTW's release

Press coverage of the survey also reported that 16% of covering employers are weighing a cut (up from 9% a year earlier), that 8% have moved to manufacturer-direct arrangements and 28% are considering it, and that coverage typically costs in the mid-$500s to mid-$600s per user per month. The 16% and 30% figures likely reflect different survey questions.

These are survey responses, not actuarial decisions. "Considering" is intent, not action. But the direction changed — and the timing, mid-open-enrollment, matters.

What's Driving It

Pharmacy spend is rising faster than employers budgeted. GLP-1s at $500+ per member per month are moving from a benefit line item to a budget conversation. Employers are responding with prior authorization requirements, step therapy (requiring failure on other agents first), or BMI-based eligibility thresholds.

MassHealth (Massachusetts Medicaid) moved first among public payers: starting January 4, 2027, tirzepatide and semaglutide require prior authorization for prediabetes, with a three-drug failure requirement (metformin + Trulicity + an SGLT2 inhibitor). Diabetes coverage is untouched. Other payers are watching.

Source: MassHealth Pharmacy Facts 289, October 30, 2026. One state only — not a national policy.

What This Means if You're Currently Covered

If your employer covers GLP-1s today, that coverage may look different in 2027. Watch your enrollment materials for:

New prior authorization requirements
BMI or diagnosis eligibility thresholds
Step therapy requirements (must try metformin or other drugs first)
Changes to which GLP-1s are on the formulary
Cost-sharing increases

What This Means if You're Not Currently Covered

Medicare GLP-1 Bridge: Launched July 1, 2026, for eligible Part D enrollees. $50/month for Wegovy, Zepbound KwikPen, or Foundayo (orforglipron), through December 31, 2027. Requires prior authorization, BMI-based eligibility, and a qualifying diagnosis. Does not count toward your Part D deductible or out-of-pocket maximum. Zepbound is KwikPen only under this program. Source: CMS.gov.

Pricing changes in 2027: Novo Nordisk is cutting US WAC pricing on all semaglutide to $675/month effective January 1, 2027. Foundayo (orforglipron) launched at a lower price point than injectable alternatives.

Manufacturer-direct programs: In October 2026, GoodRx opened a GLP-1 channel within its Employer Direct program (launched earlier in 2026), letting employers offer GLP-1s outside the traditional pharmacy benefit.

The Maintenance Question Nobody Is Asking Yet

More than half of people who start a GLP-1 for weight stop within one year: 53.6% in a 125,474-adult cohort published in JAMA Network Open. Cost and coverage changes are the most documented reasons.

After stopping, regain is the documented default — on average 0.4 kg per month in the months after discontinuation, with metabolic benefits fading around 18 months (BMJ systematic review).

The question worth asking your benefits team now, before open enrollment closes: what is the plan if coverage changes mid-therapy?

What to Track Going Into 2027

Your current GLP-1 benefit terms and any change notices from your employer
Whether your specific drug is on your plan's covered formulary and at what tier
Whether prior authorization applies and what criteria are required
Your BMI and diagnosis documentation (keeping this current makes PA approval straightforward)
Medicare Bridge eligibility criteria if you have Part D coverage

If you're a clinic or employer: the 2027 payer question is increasingly who still qualifies, not just who lost weight. Reason-coded persistence and discontinuation data will survive a payer audit. Employer-friendly averages won't.

Evidence limitation note: WTW figures are from the October 28, 2026 release (n=471); intent data, not actuarial decisions. Secondary figures (16%, 8%, 28%, cost per user) are from press coverage of the survey. MassHealth policy is one state only. Discontinuation rate: retrospective cohort, n=125,474, adults with overweight or obesity starting therapy 2018–2023. BMJ regain figure: systematic review average; individual results vary. Medicare Bridge parameters as published by CMS at the time of writing.

Sources

WTW, 2026 Best Practices in Healthcare Survey release, October 28, 2026 (n=471).
24/7 Wall St., "16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage," October 28, 2026.
Novo Nordisk, US list price reduction for Wegovy, Ozempic and Rybelsus, effective January 1, 2027.
MassHealth Pharmacy Facts 289, October 30, 2026.
CMS, Medicare GLP-1 Bridge. cms.gov
Rodriguez PJ et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025;8(1):e2457349.
BMJ systematic review on GLP-1 weight regain after discontinuation.
Pharmaceutical Commerce, "GoodRx opens employer GLP-1 channel," October 29, 2026.

Published by PeptidesGPT, which offers a paid membership. PeptidesGPT is an educational platform; this post contains no product or purchase recommendations and does not constitute benefits, legal or medical advice. Consult a licensed healthcare provider for individualized medical guidance.

GLP-1 Employer Coverage Is Falling: What It Means for Open Enrollment 2027